Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Edward H. van der Horst"'
Autor:
Thomas Thisted, F. Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H. Martin, Yoshiko Takeuchi, Kader Thiam, Robert D. Schreiber, Edward H. van der Horst
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract VISTA, an inhibitory myeloid-T-cell checkpoint, holds promise as a target for cancer immunotherapy. However, its effective targeting has been impeded by issues such as rapid clearance and cytokine release syndrome observed with previous VIST
Externí odkaz:
https://doaj.org/article/5baa81963d6e484cb872b3eac39edd59
Autor:
Gaëlle H. Martin, Alexis Gonon, Perrine Martin-Jeantet, Florence Renart-Depontieu, Zuzana Biesova, Anokhi Cifuentes, Arnab Mukherjee, Thomas Thisted, Astrid Doerner, Dean O. Campbell, Ludovic Bourré, Edward H. van der Horst, Amélie Rezza, Kader Thiam
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to p
Externí odkaz:
https://doaj.org/article/f1b517b31b7b45c781d7edf8fa9804ce
Publikováno v:
Antibodies, Vol 12, Iss 3, p 55 (2023)
Immune checkpoints and other immunoregulatory targets can be difficult to precisely target due to expression on non-tumor immune cells critical to maintaining immune homeostasis in healthy tissues. On-target/off-tumor binding of therapeutics results
Externí odkaz:
https://doaj.org/article/0e0955ff91804c98a568f65c79a9c7e1
Autor:
Léa Mélin, Emily Gesner, Sarah Attwell, Olesya A. Kharenko, Edward H. van der Horst, Henrik C. Hansen, Alexandre Gagnon
Publikováno v:
ACS Omega, Vol 6, Iss 33, Pp 21327-21338 (2021)
Externí odkaz:
https://doaj.org/article/2ac6ac4ea775409387e171e7e5b01be8
Publikováno v:
Cancer Gene Therapy. 29:859-869
CDK4/6 inhibitors significantly prolong progression-free survival in patients with advanced hormone receptor-positive (HR+) HER2-negative breast cancer. Despite recent successes, patients acquire resistance, necessitating the development of additiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b582f53dc9b948ac194b471518fa436
https://doi.org/10.1038/s41417-021-00375-9
https://doi.org/10.1038/s41417-021-00375-9
Autor:
Emily M. Gesner, Sarah Attwell, Henrik C. Hansen, Alexandre Gagnon, Olesya A. Kharenko, Edward H. van der Horst, Léa Mélin
Publikováno v:
ACS Omega, Vol 6, Iss 33, Pp 21327-21338 (2021)
ACS Omega
ACS Omega
PB1 is a bromodomain-containing protein hypothesized to act as the nucleosome-recognition subunit of the PBAF complex. Although PB1 is a key component of the PBAF chromatin remodeling complex, its exact role has not been elucidated due to the lack of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02bbdc2b24b9594bf06b687e6a6745e2
https://doaj.org/article/2ac6ac4ea775409387e171e7e5b01be8
https://doaj.org/article/2ac6ac4ea775409387e171e7e5b01be8
Autor:
Aiping Bai, Elise Renahan, Kanam Malhotra, Thomas Thisted, F. Donelson Smith, Robert H Pierce, Edward H van der Horst
Publikováno v:
Cancer Research. 83:4645-4645
Background CD39 expression is upregulated in the tumor microenvironment (TME), which is characterized by high levels of extracellular ATP (eATP) and low pH. CD39 catalyzes the rate-limiting degradation step of this immunostimulatory ATP, leading to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd7a34b58f3681343605a6f48eb49954
https://doi.org/10.1158/1538-7445.am2023-4645
https://doi.org/10.1158/1538-7445.am2023-4645
Publikováno v:
Cancer gene therapy. 29(6)
CDK4/6 inhibitors significantly prolong progression-free survival in patients with advanced hormone receptor-positive (HR+) HER2-negative breast cancer. Despite recent successes, patients acquire resistance, necessitating the development of additiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04bebe635f756fb3e9d28eb2dde30a7e
https://pubmed.ncbi.nlm.nih.gov/34385584
https://pubmed.ncbi.nlm.nih.gov/34385584
Publikováno v:
Cancer Research. 80:1750-1750
CDK4/6 inhibitors have been shown to significantly prolong progression-free survival in patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer. In spite of the great successes with the currents lines of therapies, the pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f992f6ea43aacdacb6af59a8ac1ed797
https://doi.org/10.1158/1538-7445.am2020-1750
https://doi.org/10.1158/1538-7445.am2020-1750
Autor:
Violeta Serra, Tian V. Tian, Olesya A. Kharenko, Reena G. Patel, Marc Cosín, Eric Campeau, Cyrus Calosing, Ravi Jahagirdar, Sanjay Lakhotia, Winona Oliveros, Mafalda Oliveira, Edward H. van der Horst, Joaquín Arribas, Marta Melé, Sandra Peiró, Cristina Saura, Marta Palafox
Publikováno v:
Cancer Research. 80:1282-1282
Three inhibitors of CDK4/6 kinases have been recently approved for use in combination with endocrine therapy. These inhibitors considerably increase the progression-free survival of patients with advanced Estrogen receptor (ER)-positive breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3043f5563a0acce3b28ae0ae01a83292
https://doi.org/10.1158/1538-7445.am2020-1282
https://doi.org/10.1158/1538-7445.am2020-1282